XP23829: Phase II data

XenoPort Inc. (NASDAQ:XNPT), Santa Clara, Calif. Product: XP23829 Business: Autoimmune Molecular target: Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) (NRF2) Description: Oral prodrug of monom...